CORE--INCEPTION COHORT OF RHEUMATOID ARTHRITIS PATIENTS

核心--类风湿性关节炎患者的初始队列

• 批准号: 6583190
• 负责人: James F Fries
• 金额: $ 21.52万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-08 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6583190
• 关键词: X ray; antiarthritic agent; arthritis therapy; biomedical facility; clinical research; data management; human genetic material tag; human subject; human therapy evaluation; longitudinal human study; medical outreach /case finding; microarray technology; patient care management; patient oriented research; questionnaires; rheumatoid arthritis; rheumatoid factor; statistics /biometry; tissue /organ preservation; tissue resource /registry

This Core will establish, maintain, and provide access to inception cohorts totaling over 1500 rheumatoid arthritis (RA) patients enrolled within their first year of disease and will follow these patients using standard ARAMIS protocols within full Health Assessment Questionnaire (HAQ) administration each six months, for a period of longitudinal follow-up of nine years. These cohorts are (1) large, (2) broadly representative, (3) geographically diverse, (4) encompass alternative management strategies, (5) contain DNA typing data (DRBI *0401 and *0404), and (6) include standardized central laboratory determination of CRP and Rheumatoid Factor, (7) contain frozen cells and serum for future studies, (8) enable search for causative agents in RA through use of newly available protein micro-array technology on stored serum, (9) consist of consecutively seen patients without exclusions, and (10) be maintained for long-term follow-up, including standardized reading of hand radiographs at 4 and 8 years of disease. The Core tasks builds upon investigator and staff skills at physician and patient recruitment and in maintenance of large data sets over the long- term. These inception cohorts will provide a unique and powerful resource in support of Projects 1, 2, 3 and 4 and for national and international collaborations with other investigators.

该核心将建立、维护和提供对总计超过1500名在患病第一年内入组的类风湿性关节炎（RA）患者的初始队列的访问，并将使用标准ARAMIS方案在每六个月的完整健康评估问卷（HAQ）管理中对这些患者进行随访，纵向随访期为九年。这些队列（1）规模大，（2）具有广泛代表性，（3）地理分布多样，（4）包含替代管理策略，（5）包含DNA分型数据（DRBI *0401和 *0404），和（6）包括CRP和风湿因子的标准化中心实验室测定，（7）包含冷冻细胞和血清用于未来研究，（8）通过使用新的可用蛋白微阵列技术在储存的血清上能够搜索RA中的病原体，（9）由连续观察的患者组成而没有排除，和（10）被维持用于长期随访，包括在疾病的4年和8年时手部X线照片的标准化阅读。核心任务建立在研究者和工作人员在医生和患者招募以及长期维护大型数据集方面的技能基础上。这些初期队列将为支持项目1、2、3和4以及与其他调查人员的国家和国际合作提供独特而强大的资源。